402 related articles for article (PubMed ID: 30807757)
1. Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.
Henriquez JE; Crawford RB; Kaminski NE
Toxicol Appl Pharmacol; 2019 Apr; 369():82-89. PubMed ID: 30807757
[TBL] [Abstract][Full Text] [Related]
2. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
[TBL] [Abstract][Full Text] [Related]
3. Δ
Rizzo MD; Crawford RB; Bach A; Sermet S; Amalfitano A; Kaminski NE
J Pharmacol Exp Ther; 2019 Oct; 371(1):191-201. PubMed ID: 31383729
[TBL] [Abstract][Full Text] [Related]
4. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis.
Xu H; Cheng CL; Chen M; Manivannan A; Cabay L; Pertwee RG; Coutts A; Forrester JV
J Leukoc Biol; 2007 Sep; 82(3):532-41. PubMed ID: 17537989
[TBL] [Abstract][Full Text] [Related]
6. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor 2 activation decreases severity of cyclophosphamide-induced cystitis via regulating autophagy.
Liu Q; Wu Z; Liu Y; Chen L; Zhao H; Guo H; Zhu K; Wang W; Chen S; Zhou N; Li Y; Shi B
Neurourol Urodyn; 2020 Jan; 39(1):158-169. PubMed ID: 31729056
[TBL] [Abstract][Full Text] [Related]
8. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.
Fu W; Taylor BK
Neurosci Lett; 2015 May; 595():1-6. PubMed ID: 25849525
[TBL] [Abstract][Full Text] [Related]
9. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
10. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
Rajasekaran M; Brents LK; Franks LN; Moran JH; Prather PL
Toxicol Appl Pharmacol; 2013 Jun; 269(2):100-8. PubMed ID: 23537664
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
12. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
14. Cannabichromene is a cannabinoid CB
Udoh M; Santiago M; Devenish S; McGregor IS; Connor M
Br J Pharmacol; 2019 Dec; 176(23):4537-4547. PubMed ID: 31368508
[TBL] [Abstract][Full Text] [Related]
15. Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.
Springs AE; Karmaus PW; Crawford RB; Kaplan BL; Kaminski NE
J Leukoc Biol; 2008 Dec; 84(6):1574-84. PubMed ID: 18791168
[TBL] [Abstract][Full Text] [Related]
16. Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.
Henriquez JE; Rizzo MD; Schulz MA; Crawford RB; Gulick P; Kaminski NE
J Acquir Immune Defic Syndr; 2017 Aug; 75(5):588-596. PubMed ID: 28692581
[TBL] [Abstract][Full Text] [Related]
17. A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes.
Van Hove L; Kim KR; Arrick DM; Mayhan WG
Microvasc Res; 2021 Jan; 133():104077. PubMed ID: 32979391
[TBL] [Abstract][Full Text] [Related]
18. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.
Lombard C; Nagarkatti M; Nagarkatti P
Clin Immunol; 2007 Mar; 122(3):259-70. PubMed ID: 17185040
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid CB
Olianas MC; Dedoni S; Onali P
Life Sci; 2021 Jul; 276():119407. PubMed ID: 33794254
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB2 receptor activation attenuates cytokine-evoked mucosal damage in a human colonic explant model without changing epithelial permeability.
Harvey BS; Nicotra LL; Vu M; Smid SD
Cytokine; 2013 Aug; 63(2):209-17. PubMed ID: 23706402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
